Navigation Links
K-V Pharmaceutical Company Receives Notification From New York Stock Exchange of Compliance With Quantitative Continued Listing Standards
Date:9/2/2010

ital and consumer spending;
  • the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized;
  • the possibility of not obtaining FDA approvals or delay in obtaining FDA approvals, including with respect to Gestiva™, as well as the number of preterm births for which Gestiva™ may be prescribed, its safety profile and side effects profile;
  • acceptance of and demand for the Company's new pharmaceutical products or current products upon their return to the marketplace;
  • the introduction and impact of competitive products and pricing, including as a result of so-called authorized generic drugs;
  • new product development and launch, including the possibility that any product launch may be delayed;
  • reliance on key strategic acquisitions;
  • the availability of raw materials and/or products manufactured for the Company under contract manufacturing agreements with third parties;
  • the regulatory environment, including regulatory agency and judicial actions and changes in applicable laws or regulations;
  • fluctuations in revenues;
  • the difficulty of predicting international regulatory approvals, including timing;
  • the difficulty of predicting the pattern of inventory movements by the Company's customers;
  • the impact of competitive response to the Company's sales, marketing and strategic efforts, including introduction or potential introduction of generic or competing products against products sold by the Company and its subsidiaries;
  • risks that the Company may not ultimately prevail in litigation, including product liability lawsuits and challenges to its intellectual property rights by actual or potential competitors or to its ability to market generic products due to brand company patents and challenges to other companies' introduction or potential introduction of generic or competing products by third parties against produc
    '/>"/>

  • SOURCE K-V Pharmaceutical Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
    2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
    9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... Aug. 31, 2015 Regen BioPharma, Inc. (OTCBB: ... a novel means of delivering its patented (US ... liver tumors utilizing a clinically approved formulation as ... hurdles with gene silencing therapeutics in which the ... the whole body.  By utilizing a local delivery ...
    (Date:8/31/2015)... 2015 BioLight Life ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, today announced that its cancer ... several new genetic markers with high potential to ... with bisphosphonate drugs and was able to repeat ...
    (Date:8/31/2015)... 31, 2015  AMRI (NASDAQ: AMRI ) ... collaboration focused on the development, manufacture and marketing ... ("APIs"). The collaboration combines Saneca,s strength in extracting ... developing and manufacturing controlled substance APIs with AMRI,s ... processes into these facilities. The collaboration will also ...
    Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4
    ... April 28, 2011 There,s a sea change sweeping across the ... do they need to carry bottles of liquid and slow-acting pills ... a car, plane or when watching a 3-D movie. ... in the battle against motion-sickness, allowing people to easily avoid nausea ...
    ... (NYSE: CVS ) today announced it expects ... business of Universal American on Friday, April 29, 2011. ... shareholders cash consideration of $1.25 billion plus the excess ... Part D business, less Universal American,s outstanding trust preferred ...
    Cached Medicine Technology:Zentrip Offers a 'Sea Change' in Stopping the Distress from Motion Sickness 2CVS Caremark to Complete Acquisition of Universal American's Medicare Part D Business 2CVS Caremark to Complete Acquisition of Universal American's Medicare Part D Business 3
    (Date:8/31/2015)... ... 31, 2015 , ... CareSource, a nonprofit Ohio-based health plan, ... capacity, Michael will provide strategic leadership for CareSource’s marketing, branding, corporate communications and ... have contributed to the company’s rapid growth. As the CareSource business model expands ...
    (Date:8/31/2015)... BAY PINES, FL (PRWEB) , ... August 31, 2015 , ... ... accessible, high quality healthcare to Veterans residing across southwest Florida by hiring more doctors ... added to the list of expanded services. , In early July, Dr. Anthony Jabre ...
    (Date:8/31/2015)... ... September 01, 2015 , ... ... for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy ”. , ... Traumatic brain injury has been largely untreatable - with mostly palliative treatments only ...
    (Date:8/31/2015)... ... , ... Since 1946, the doctors and staff at Clifton Dental Associates have ... arrives at the office, the staff will make them feel welcome and comfortable. ... create a complete dental treatment plan that is unique to each smile! NJ ...
    (Date:8/31/2015)... ... August 31, 2015 , ... With the FCPX LUT Soft pack from Pixel Film Studios, editors ... Table that contains a mathematical formula for modifying an image. The LUT changes every pixel's ... CUBE LUT files. , FCPX LUT Soft requires Final Cut Pro X 10.2 or ...
    Breaking Medicine News(10 mins):Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 3Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2
    ... 2011 The children most likely to walk or cycle ... and in an economically disadvantaged home, according to survey results ... Roman Pabayo of the University of Montreal Hospital Research Centre ... study is unique in that it follows the same group ...
    ... SATURDAY, July 2 (HealthDay News) -- Staying hydrated is critical ... have different hydration needs, so you need to assess your ... of Tennessee at Chattanooga. "Sweat rate is very simple ... as possible; exercise for half an hour and don,t drink ...
    ... News) -- Nausea and vomiting after waking from general anesthesia ... from 122 patients with severe postoperative nausea and vomiting (PONV) ... initially identified 41 genetic targets (single nucleotide polymorphisms -- SNPs) ... them to at least one SNP that was common to ...
    ... contain baked milk into the diets of children who have ... according to a study conducted at Mount Sinai School of ... the May 23 issue of the Journal of Allergy ... 2 to 17 years old, who were diagnosed with milk ...
    ... 1 (HealthDay News) -- Increasing daily soluble fiber intake may ... other substances linked to a host of chronic diseases, according ... found just under the skin, visceral fat is located deep ... Researchers at Wake Forest Baptist Medical Center found the way ...
    ... 1, 2011 Surgery and all its implications can be ... dread sometimes disfiguring scars. Now a UT Southwestern Medical ... that makes scarring virtually invisible yet is just as effective ... with minimally invasive surgery, leave the child with up to ...
    Cached Medicine News:Health News:Urban children are healthier commuters than rural teens 2Health News:How to Stay Hydrated in Hot Weather 2Health News:Foods with baked milk may help build tolerance in children with dairy allergies 2Health News:Soluble Fiber Appears Key to Trimming 'Bad Fat' 2Health News:UT Southwestern pediatric urologist develops procedure to eliminate scarring in kidney surgeries 2
    ... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
    ... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTC/1Q chairs are recommended for ... clean room, static control, health care ...
    ... chairs with concave seats and ... • Select options like seats, ... glides. • BTT/1P chairs are ... industry, education, laboratory, clean room, ...
    ... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With tubular ...
    Medicine Products: